Clinical Trials Logo

Clinical Trial Summary

This is single institution cases series review of histological and clinical data


Clinical Trial Description

Investigators will retrieve from the database of the Rizzoli institute all the cases with a histological diagnosis of Ewing sarcoma from 01 Jan 1982 to 31 Dic 2012 ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03968471
Study type Observational
Source Istituto Ortopedico Rizzoli
Contact
Status Completed
Phase
Start date May 13, 2019
Completion date January 15, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT06068075 - Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD N/A
Completed NCT01825902 - 18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma Early Phase 1
Completed NCT00618813 - Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors N/A
Withdrawn NCT05116800 - Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Phase 2
Recruiting NCT04845893 - Observational Study on Skeletal Ewing's Sarcoma
Withdrawn NCT01795430 - Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma N/A
Recruiting NCT05033288 - Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
Completed NCT00516295 - Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma Phase 2
Completed NCT00674193 - Evaluating Dactinomycin and Vincristine in Young Patients With Cancer N/A
Completed NCT05024253 - Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements. Phase 3
Recruiting NCT05395741 - Regorafenib in Patients With Refractory Primary Bone Tumors Phase 1/Phase 2